D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...

Jay will begin with a review of recent corporate updates and discuss our clinical programs for DuraVu in wet AMD and DME.

Ocular Therapeutix Inc (OCUL) showcases robust trial progress and financial positioning, while navigating regulatory and ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...

Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...

D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market ...

Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...

Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a ...

4D Molecular Therapeutics has sold the Asia-Pacific rights to its eye gene therapy to Otsuka Pharmaceutical, securing $85 ...

Presenters at the AAO 2025 meeting outlined a future for retinal care that reduces patient burden by reconsidering treatment delivery methods.

Second-generation anti-VEGF agents, like aflibercept 8 mg and faricimab, show improved efficacy and treatment durability in ...

A large propensity-matched retrospective cohort study showed a small but statistically significant 7% increase in new-onset ...